Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to $3.1 million.

  • Therapeutics' Change in Accured Expenses rose 4452.11% to $3.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$8.5 million, marking a year-over-year decrease of 215.32%. This contributed to the annual value of -$8.5 million for FY2024, which is 215.32% down from last year.
  • As of Q4 2024, Therapeutics' Change in Accured Expenses stood at $3.1 million, which was up 170.32% from -$4.4 million recorded in Q3 2024.
  • In the past 5 years, Therapeutics' Change in Accured Expenses ranged from a high of $7.3 million in Q1 2023 and a low of -$6.4 million during Q2 2024.
  • Its 3-year average for Change in Accured Expenses is $215,500, with a median of $301,000 in 2022.
  • In the last 5 years, Therapeutics' Change in Accured Expenses crashed by 543.51% in 2023 and then soared by 4,452.11% in 2024.
  • Quarterly analysis of 5 years shows Therapeutics' Change in Accured Expenses stood at -$2.8 million in 2020, then rose by 7.06% to -$2.6 million in 2021, then soared by 89.95% to -$263,000 in 2022, then soared by 73.00% to -$71,000 in 2023, then soared by 4,452.11% to $3.1 million in 2024.
  • Its Change in Accured Expenses stands at $3.1 million for Q4 2024, versus -$4.4 million for Q3 2024 and -$6.4 million for Q2 2024.